来特莫韦对接受异基因造血干细胞移植的儿科患者巨细胞病毒的预防作用。 - Suppr

Letermovir prophylaxis for cytomegalovirus in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.

作者信息

Wang Qingwei, Liu Minyuan, Zhang Senlin, Gao Li, Chu Xinran, Li Bohan, Cheng Shengqin, Tian Yuanyuan, Zhang Yongping, Hu Yixin, Li Jie, Lu Jun, Xiao Peifang, Liu Hu, Hu Shaoyan

机构信息

Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China.

Jiangsu Pediatric Hematology and Oncology Center, Suzhou, China.

出版信息

Bone Marrow Transplant. 2025 Mar;60(3):422-424. doi: 10.1038/s41409-024-02502-0. Epub 2025 Jan 7.

DOI:10.1038/s41409-024-02502-0

PMID:39775127

Abstract

摘要

相似文献

Letermovir prophylaxis for cytomegalovirus in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.来特莫韦对接受异基因造血干细胞移植的儿科患者巨细胞病毒的预防作用。

Bone Marrow Transplant. 2025 Mar;60(3):422-424. doi: 10.1038/s41409-024-02502-0. Epub 2025 Jan 7.

Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后接受来特莫韦预防治疗时巨细胞病毒再激活的危险因素分析

Transpl Infect Dis. 2022 Dec;24(6):e13904. doi: 10.1111/tid.13904. Epub 2022 Jul 28.

Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong.在香港，异体造血干细胞移植受者中，来特莫韦作为巨细胞病毒预防的成本效益。

J Med Econ. 2020 Dec;23(12):1485-1492. doi: 10.1080/13696998.2020.1843321. Epub 2020 Nov 12.

Letermovir as Cytomegalovirus Prophylaxis in a Pediatric Cohort: A Retrospective Analysis.来特莫韦用于儿童队列巨细胞病毒预防：一项回顾性分析

Transplant Cell Ther. 2023 Jan;29(1):62.e1-62.e4. doi: 10.1016/j.jtct.2022.10.005. Epub 2022 Oct 13.

Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis.高危异基因造血细胞移植患者接受乐特韦预防后的巨细胞病毒事件。

Transpl Infect Dis. 2021 Aug;23(4):e13619. doi: 10.1111/tid.13619. Epub 2021 May 5.

Extended duration letermovir in allogeneic hematopoietic stem cell transplant.延长疗程的来特莫韦用于异基因造血干细胞移植。

Transpl Immunol. 2023 Dec;81:101936. doi: 10.1016/j.trim.2023.101936. Epub 2023 Sep 26.

Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.来特莫韦用于预防单倍体相合及配型不合的成年供者异基因造血细胞移植中巨细胞病毒再激活，移植后使用环磷酰胺预防移植物抗宿主病。

Transplant Cell Ther. 2021 Jan;27(1):85.e1-85.e6. doi: 10.1016/j.bbmt.2020.10.009. Epub 2020 Oct 11.

Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study.来特莫韦用于异基因造血细胞移植后巨细胞病毒预防的真实世界经验：一项多中心观察性研究。

J Infect. 2024 Aug;89(2):106220. doi: 10.1016/j.jinf.2024.106220. Epub 2024 Jul 1.

Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.来特莫韦用于异基因造血细胞移植受者原发性和继发性巨细胞病毒预防的真实世界经验。

Transpl Infect Dis. 2019 Dec;21(6):e13187. doi: 10.1111/tid.13187. Epub 2019 Oct 21.

Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.真实世界经验：在使用T细胞清除作为移植物抗宿主病预防措施的情况下，研究来特莫韦用于高危异基因造血干细胞患者巨细胞病毒预防的疗效。

Transpl Immunol. 2023 Feb;76:101769. doi: 10.1016/j.trim.2022.101769. Epub 2022 Dec 2.

引用本文的文献

When hematology meets ophthalmology: Cytomegalovirus retinitis in pediatric stem cell recipients.当血液学遇上眼科学：儿科干细胞接受者中的巨细胞病毒性视网膜炎

World J Stem Cells. 2025 Jul 26;17(7):107153. doi: 10.4252/wjsc.v17.i7.107153.

本文引用的文献

Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP).来特莫韦治疗儿童异基因造血干细胞移植后巨细胞病毒感染：意大利儿科血液肿瘤学会感染病工作组的真实世界研究（AIEOP）。

Bone Marrow Transplant. 2024 Apr;59(4):505-512. doi: 10.1038/s41409-024-02209-2. Epub 2024 Jan 25.

Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis.来特莫韦预防下造血干细胞移植受者的人巨细胞病毒特异性 T 细胞重建和迟发性巨细胞病毒感染。

Transplant Cell Ther. 2022 Apr;28(4):211.e1-211.e9. doi: 10.1016/j.jtct.2022.01.008. Epub 2022 Jan 15.

Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation.造血细胞移植后使用乐韦莫及预防治疗后巨细胞病毒特异性 T 细胞的重建。

Blood. 2021 Jul 8;138(1):34-43. doi: 10.1182/blood.2020009396.

Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation.在来特莫韦预防异基因造血细胞移植中巨细胞病毒感染的III期试验中，随机分组时检测到巨细胞病毒DNA的患者的结局。

Am J Transplant. 2020 Jun;20(6):1703-1711. doi: 10.1111/ajt.15764. Epub 2020 Jan 18.

Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study.年龄相关因素对造血细胞移植后儿童和成人感染并发症谱的影响：来自全国性研究的经验。

Ann Hematol. 2019 Sep;98(9):2197-2211. doi: 10.1007/s00277-019-03755-2. Epub 2019 Jul 18.

Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study.抢先治疗时代造血干细胞移植后巨细胞病毒载量与死亡率：一项回顾性队列研究

Lancet Haematol. 2016 Mar;3(3):e119-27. doi: 10.1016/S2352-3026(15)00289-6. Epub 2016 Feb 20.

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.早期巨细胞病毒再激活在当前时代仍与移植相关死亡率增加相关：一项国际骨髓移植登记处（CIBMTR）的分析。

Blood. 2016 May 19;127(20):2427-38. doi: 10.1182/blood-2015-11-679639. Epub 2016 Feb 16.

CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT.CMV 血清学状态在异基因造血干细胞移植后新发急性白血病患者中仍具有重要的预后影响：来自 EBMT 急性白血病工作组的报告。

Blood. 2013 Nov 7;122(19):3359-64. doi: 10.1182/blood-2013-05-499830. Epub 2013 Sep 13.

The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.新型抗巨细胞病毒化合物 AIC246（来特莫韦）通过一种特定的抗病毒机制抑制人类巨细胞病毒复制，该机制涉及病毒末端酶。

J Virol. 2011 Oct;85(20):10884-93. doi: 10.1128/JVI.05265-11. Epub 2011 Jul 13.

Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation.异基因造血干细胞移植后对巨细胞病毒的免疫重建：宿主因素、药物治疗及亚临床再激活的影响

Blood. 2003 Oct 15;102(8):3060-7. doi: 10.1182/blood-2002-11-3472. Epub 2003 Jul 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Letermovir prophylaxis for cytomegalovirus in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献